While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are ...

JMP Securities analyst Silvan Tuerkcan has reiterated their bullish stance on VOR stock, giving a Buy rating on November 8. Silvan ...

Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s ...

Stephens analyst has initiated coverage on ADC Therapeutics SA (NYSE:ADCT), a commercial-stage oncology-focused biotechnology ...

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...

A disease historically associated with malnourishment on sailing vessels may have a new, modern culprit: Bariatric surgery.

Induction chemotherapy shows significant improvements for survival in patients with locally advanced cervical cancer.

and a further 36 in hematological malignancies. For more than 25 years, Global Healing has been helping health-conscious ...

HC Wainwright reaffirmed their buy rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research note issued to investors on Friday,Benzinga reports. The firm currently has a $17.50 price ...

Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, ...

A PA Student used his experience in the military, and his own health journal, to help other veterans apply and receive ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).